A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

Study Identifier:

SEP361-308

ClinicalTrials.gov Identifier:

NCT05628103

EudraCT Identifier:

N/A

Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Study Contact Information:

N/A

Study Complete

Subscribe to Updates

Study Details

Medical Condition

Schizophrenia

Study Drug

Drug: SEP-363856

Date

Dec 2022 - Apr 2024

Phase 1

Phase 2

Phase 3

Phase 4

N/A

Patient Requirements

Sex: Female & Male

Age: 18 - 65 Years

Requirements Information

Protocol Summary

This study will evaluate how well SEP-363856 works and how safe it is in people with schizophrenia that switch to SEP-363856 from their current antipsychotic medication.

Study Locations

Location

Status

Location

Advanced Research Center, Inc.

Anaheim, California, United States, 92805

Status

N/A

Location

Clinical Innovations Inc.

Bellflower, California, United States, 90706

Status

N/A

Location

ProScience Research Group

Culver City, California, United States, 90230

Status

N/A

Location

Collaborative Neuroscience Research, LLC

Garden Grove, California, United States, 92845

Status

N/A

Location

Synergy San Diego

Lemon Grove, California, United States, 91945

Status

N/A

Location

Clinical Innovations, Inc

Riverside, California, United States, 92506

Status

N/A